Overview

An Open Label Extension Study of the Efficacy of MORAb-003

Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
An open label extension of the MORAb-003-002 study in order to continue the active patients in the MORAb-003-002 study on maintenance MORAb-003 infusions after the main study is closed.
Phase:
Phase 2
Details
Lead Sponsor:
Morphotek
Treatments:
Farletuzumab